Table 2 Patients and baseline characteristics
Characteristic | |
|---|---|
Age (yr), n (%) | |
Median | 47.5 |
Range | 28–61 |
Sex, male/female, n (%) | 8 (44.4)/10 (55.6) |
Primary lesion | |
Pancreas | 14 (77.8) |
Rectum | 1 (5.6) |
Unknown origin | 3 (16.7) |
Site of target lesions, n (%) | |
Pancreas (primary tumor) | 11 (25.0) |
Liver | 25 (56.8) |
Mesenteric lymph node | 1 (2.3) |
Retroperitoneal lymph node | 3 (6.8) |
Pelvic cavity | 4 (9.1) |
Pathological classification, n (%) | |
Grade 1 | 2 (11.1) |
Grade 2 | 14 (77.8) |
Grade 3 | 2 (11.1) |
Tumor functionality, n (%) | |
Nonfunctioning | 16 (88.9) |
Functioning | 2 (11.1) |
Previous treatments, n (%) | |
None | 11 (61.1) |
Surgery | 4 (22.2) |
Octreotide | 1 (5.6) |
Transarterial chemoembolization | 1 (5.6) |
Transarterial chemoembolization & Octreotide | 1 (5.6) |
Duration of sunitinib (months) | |
Median | 6.8 |
Range | 1.0–22.7 |
Time between initiation and first evaluation (months) | |
Median | 2.3 |
Range | 1.4–3.1 |
Duration of follow-up (months) | |
Median | 17.3 |
Range | 4.3–47.9 |